by pixalien | Jun 2, 2021 | General
June 17, 2021: OncoSpherix’s CEO Dr. Margaret K. Offermann is scheduled to present at 1 PM ET a webinar as part of Crystal Pharma’s “Molecules to Medicine” series. The title of her presentation is “The role of collaboration in optimizing the development of HIF...
by pixalien | May 6, 2021 | General
Margaret K Offermann, CEO of OncoSpherix, was a keynote speaker at the 2nd Meridian Drug Discovery Virtual Event. The title of her presentation was “Enhancing chemical properties of dual HIF-1 and HIF-2 inhibitors for treating advanced cancers”...
by pixalien | Jan 29, 2021 | General
The Georgia Research Alliance (GRA) awarded a Phase 2A grant of $53,334 to Dr. Hans Grossniklaus for studies that test OncoSpherix’s lead clinical candidate, the dual HIF inhibitor 64B, as part of combination therapy with tyrosine kinase inhibitors in mouse models of...
by pixalien | Jan 28, 2021 | General
Kenneth Moch joins the OncoSpherix team as Special Advisor to the CEO: “It is a privilege to have Ken Moch serve as my advisor as we build OncoSpherix into a successful drug development company that is advancing agents that should benefit patients with many types of...
by pixalien | Jan 26, 2021 | General
Robert Scott, MD, has joined the Board of Directors of OncoSpherix. Dr. Scott has held leadership positions in global Pharma for over thirty years. At Pfizer, he developed Lipitor and Norvasc. He also invented and developed the first commercially available Polypill,...
